DNV-3

N/A

Report date: 2026/02/10 20:00:22
First In Class

Base Information

Drug NameDNV-3
Drug Alias NameDNV-3DNV3
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsSolid tumoursSkin NeoplasmsMelanoma +[5
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Active IndicationsSolid tumoursSkin NeoplasmsMelanoma +[4
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A